Benjamin Besse

Also affiliated with Institut Gustave Roussy

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

9in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 9 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Supplementary Table S2 from Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial

(2023)10.1158/1078-0432.22481301

Top 100%

0DataRank

Top 100%0 citations

Justin F. Gainor, Geoffrey R. Oxnard, Daniel S.W. Tan, Dwight H. Owen, Byoung Chul Cho +16 more

Papers

Driven by 16 papers — median percentile 0. Top paper: “Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study”.

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study

The Lancet Oncology(2021)10.1016/s1470-2045(21)00247-3

N/A

5.0DataRank · unranked

445 citations

Giuseppe Curigliano, Dong‐Wan Kim, Ki Hyeong Lee, Benjamin Besse, Christina S. Baik +20 more

Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-0800

N/A

3.5DataRank · unranked

140 citations

Justin F. Gainor, Geoffrey R. Oxnard, Daniel Shao-Weng Tan, Dwight H. Owen, Byoung Chul Cho +16 more

Hypersensitivity Reactions to Selpercatinib Treatment With or Without Prior Immune Checkpoint Inhibitor Therapy in Patients With NSCLC in LIBRETTO-001

Journal of Thoracic Oncology(2022)10.1016/j.jtho.2022.02.004

N/A

2.5DataRank · unranked

57 citations

Christian Rolfo, Alexander Drilon, Mario E. Lacouture, Benjamin Besse, Kōichi Goto +10 more

Understanding and Overcoming Resistance to Selective FGFR Inhibitors across FGFR2 -Driven Malignancies

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-1834

N/A

1.5DataRank · unranked

39 citations

Yohann Loriot, Floriane Brayé, Damien Vasseur, Rastislav Bahleda, Ludovic Bigot +15 more

Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial

The Lancet Oncology(2022)10.1016/s1470-2045(22)00518-6

N/A

0.996DataRank · unranked

763 citations

Luis Paz-Ares, Sandrine Marreaud, Urania Dafni, Kersti Oselin, Libor Havel +16 more

Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer

Nature Medicine(2022)10.1038/s41591-021-01655-5

N/A

0.975DataRank · unranked

665 citations

Bertrand Routy, Andrew Maltez Thomas, Valerio Iebba, Gérard Zalcman, S. Friard +38 more

SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas

Nature Genetics(2015)10.1038/ng.3399

N/A

0.887DataRank · unranked

370 citations

Sarah Watson, Gaelle Pierron, Vincent Thomas de Montpreville, Stelly Ballet, Nelly Firmin +27 more

NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations

Cancer Discovery(2024)10.1158/2159-8290.cd-24-0231

N/A

0.587DataRank · unranked

49 citations

Joshua C. Horan, Anupong Tangpeerachaikul, Aurélie Swalduz, Augusto Valdivia, Melissa L. Johnson +23 more

Crizotinib Primary Resistance Overcome by Ceritinib in a Patient with ALK-Rearranged Non-Small Cell Lung Cancer

Tumori Journal(2016)10.5301/tj.5000520

N/A

0.560DataRank · unranked

9 citations

Caroline Caramella, Nathalie Auger, David Planchard, Julien Adam, Ludovic Lacroix +6 more

Surrogate markers of intestinal dysfunction associated with survival in advanced cancers

OncoImmunology(2025)10.1080/2162402x.2025.2484880

N/A

0.442DataRank · unranked

18 citations

Damien Drubay, Carolina Alves Costa Silva, Federica Marmorino, Giacomo Vitali, Gianmarco Piccinno +26 more

First-Line Pembrolizumab with or Without Platinum Doublet Chemotherapy in Non-Small-Cell Lung Cancer Patients with PD-L1 Expression ≥50%

Future Oncology(2021)10.2217/fon-2020-1202

N/A

0.425DataRank · unranked

16 citations

C. Chouaïd, Maurice Pérol, Benjamin Besse, Laurent Greillier, Olivier Bylicki +8 more

Meta-Analysis on the Combination of Chemotherapy With Programmed Death-Ligand 1 and Programmed Cell Death Protein 1 Blockade as First-Line Treatment for Unresectable Pleural Mesothelioma

Journal of Thoracic Oncology(2024)10.1016/j.jtho.2023.08.004

N/A

0.373DataRank · unranked

11 citations

Massimo Di Maio, Jordi Remon, Paolo Bironzo, Carlo Genova, Francesco Facchinetti +7 more

Exploring the optimal use of alectinib

The Lancet Respiratory Medicine(2019)10.1016/s2213-2600(19)30117-1

N/A

0.268DataRank · unranked

2 citations

Christophe Massard, Benjamin Besse, Diego Enrico

Efficacy of Neratinib-Based Therapy in ERBB2-Mutant Lung Adenocarcinomas: Findings From 2 International Phase 2 Studies

Clinical Lung Cancer(2025)10.1016/j.cllc.2025.09.009

N/A

0.104DataRank · unranked

1 citations

Leena Gandhi, Vignesh Ravichandran, Benjamin Besse, Julien Mazières, Geoffrey I. Shapiro +20 more

Supplementary Table S2 from Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial

(2023)10.1158/1078-0432.22481301

Top 100%

0DataRank

Top 100%0 citations

Justin F. Gainor, Geoffrey R. Oxnard, Daniel S.W. Tan, Dwight H. Owen, Byoung Chul Cho +16 more

Data from Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial

(2023)10.1158/1078-0432.c.6530655.v1

N/A

0DataRank · unranked

0 citations

Justin F. Gainor, Geoffrey R. Oxnard, Daniel S.W. Tan, Dwight H. Owen, Byoung Chul Cho +16 more

Benjamin Besse

Indexed papers

Top data-sharing exemplar

Papers